UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2016
CYTOMX THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-37587 | 27-3521219 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 515-3185
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01.Other Events.
On December 5, 2016, CytomX Therapeutics, Inc. issued a press release announcing that Bristol-Myers Squibb selected the fourth target under the Collaboration and License Agreement between them (the “Agreement”) and triggered a $15 million selection payment in accordance with the Agreement. This constitutes the final target selection under the Agreement. The full text of the press release is furnished as Exhibit 99.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| | | | | | |
Date: December 5, 2016 | | | CYTOMX THERAPEUTICS, INC. |
| | | |
| | | | By: | | /s/ Cynthia J. Ladd |
| | | | | | Cynthia J. Ladd |
| | | | | | Senior Vice President and General Counsel |
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
99.1 | | Press release titled “CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration” issued by CytomX Therapeutics, Inc. on December 5, 2016. |
| |
